We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Endologix Inc | NASDAQ:ELGX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.22 | 0.2344 | 0.24 | 0 | 01:00:00 |
|
|
|
|
|
☒
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
|
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
68-0328265
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification Number)
|
Large Accelerated Filer
|
|
☐
|
Accelerated Filer
|
|
☒
|
Non-accelerated Filer
|
|
☐
|
Smaller Reporting Company
|
|
☒
|
|
|
|
Emerging Growth Company
|
|
☐
|
Title of each class
|
Trading Symbol(s) (1)
|
Name of each exchange on which registered
|
Common Stock
|
N/A
|
The Nasdaq Stock Market, LLC
|
(1)
|
On July 16, 2020, the ‘NASDAQ Stock Market delisted the Company’s common stock. As of the date of this Form 10-Q, a Form 25 has not been filed with the Securities and Exchange Commission (the “SEC”) to delist the Common Stock of Endologix, Inc. The deregistration of the Common Stock under section 12(b) of the Securities Exchange Act of 1934 will be effective 90 days after filing of the Form 25. Following deregistration of the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, the Common Stock shall remain registered under Section 12(g) of the Securities Exchange Act of 1934. Beginning on July 16, 2020, the Common Stock was quoted on the OTC Pink Market under the symbol “ELGXQ.”
|
|
|
|
|
|
Item 6.
|
EXHIBIT INDEX
|
|
|
|
|
Incorporated by Reference
|
|
|
||||
Exhibit Number
|
|
Exhibit Description
|
|
Form
|
|
Exhibit
|
|
Filing Date
|
|
Filed Herewith
|
|
Promissory Note, dated May 1, 2020, from Bank of America, N.A.
|
|
8-K
|
|
10.1
|
|
5/11/20
|
|
|
|
|
Amendment to Facility Agreements, dated May 4, 2020, by and among the Company, Deerfield ELGX Revolver, LLC and Deerfield Private Design Fund I.V., L.P.
|
|
8-K
|
|
10.2
|
|
5/11/20
|
|
|
|
|
Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
10-Q
|
|
31.1
|
|
05/27/2020
|
|
|
|
|
Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
10-Q
|
|
31.2
|
|
05/27/2020
|
|
|
|
|
Certification of Principal Executive Officer pursuant to Rule 13a-14(a)31.3 or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
|
|
|
X
|
|
|
Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
|
|
|
X
|
|
|
|
Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
10-Q
|
|
32.1
|
|
05/27/2020
|
|
|
|
|
Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
10-Q
|
|
32.2
|
|
05/27/2020
|
|
|
101.INS
|
|
XBRL Instance Document.
|
|
|
|
|
|
|
|
X
|
101.SCH
|
|
XBRL Taxonomy Extension Schema
|
|
|
|
|
|
|
|
X
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase Document.
|
|
|
|
|
|
|
|
X
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document.
|
|
|
|
|
|
|
|
X
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Link Base Document
|
|
|
|
|
|
|
|
X
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document.
|
|
|
|
|
|
|
|
X
|
*
|
The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, shall not be deemed “filed” by the registrant for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any of the registrant’s filings under the Securities Act or the Exchange Act, irrespective of any general incorporation language contained in any such filing.
|
|
|
ENDOLOGIX, INC.
|
|
|
|
Date:
|
August 7, 2020
|
/s/ John Onopchenko
|
|
|
Chief Executive Officer
(Principal Executive Officer) |
|
|
|
|
|
|
Date:
|
August 7, 2020
|
/s/ Cynthia Buch Pinto
|
|
|
Interim Chief Financial Officer
(Principal Financial Officer)
|
|
|
|
1 Year Endologix Chart |
1 Month Endologix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions